Kornimate/medical-research-clean huggingface dataset:
efficacy and safety of changkang granule in the treatment of diarrhea-predominant irritable bowel syndrome (ibs-d)

Conditions: Irritable Bowel Syndrome with Diarrhea

Summary: the aim of this study is to evaluate the efficacy and safety of changkang granule as compared to placebo over a 8-week treatment period and explore tcm syndrome types.

the clinical phase of the study comprises up to 2 weeks of screening for patient's eligibility, a 2-week run-in period , a 8-week double-blind treatment period, and a 4-week safety follow-up. patients report their ibs-related symptoms daily from run-in until end of treatment.

Eligibility criteria:
inclusion criteria: 1. the patients with diarrhea predominant irritable bowel syndrome (ibs-d) met rome iv criteria; 2. it is in accordance with the syndrome differentiation standard of tcm, such as the syndrome of liver qi multiplying spleen, spleen stomach weakness, spleen kidney yang deficiency or large intestine damp heat syndrome; 3. male or female aged 18 to 65 years (including the boundary value); 4. the weekly mean nrs score of abdominal pain was ≥ 3.0, and the number of days with stool type 6 or 7 was more than 2 days per week; 5. ibs-sss score\>175; 6. signed informed consent voluntarily. exclusion criteria: 1. patients with ibs-c、ibs-m or ibs-u； 2. those who had been diagnosed with organic diseases of digestive system, such as inflammatory bowel disease, intestinal tuberculosis, intestinal tumor, etc., or still combined with peptic ulcer and infectious diarrhea; 3. patients were diagnosed with similar symptoms of irritable bowel syndrome in the past, such as eosinophilic enteritis, collagen enteritis, lactose intolerance, etc; 4. patients with non intestinal diseases of digestive system, such as tuberculous peritonitis, gallstones, liver cirrhosis, chronic pancreatitis, etc; 5. previous diagnosis of systemic diseases affecting gastrointestinal function, such as hyperthyroidism or hypothyroidism, endometriosis, chronic renal insufficiency, autoimmune diseases, diabetes, etc 6. with history of abdominal surgery (e.g., cholecystectomy); 7. patients with severe cardiovascular disease, liver, kidney and other major organ diseases, hematopoietic system diseases, tumor, nervous or mental system diseases (such as severe depression, severe anxiety) 8. those who could not stop using concomitant drugs (prokinetic agents, anticholinergics, calcium channel blockers, 5-ht3 receptor antagonists, antidiarrheal agents, antacids, antidepressants, antianxiety drugs, intestinal flora regulators, etc.) that affected gastrointestinal motility and function ; 9. taking emergency medication in the run-in period； 10. pregnant or lactating women； 11. those who are allergic to the test drug, emergency drug and its ingredients； 12. suspected or confirmed history of alcohol and drug abuse; 13. patients who participated in other clinical trials within one month before enrollment; 14. the researchers believe that others are not suitable for clinical trials.

Keywords: changkang granule
effect of intrapulmonary percussion ventilation on deposition of inhaled aerosols in idiopathic pulmonary fibrosis

Conditions: Idiopathic Pulmonary Fibrosis

Summary: this protocol aims to evaluate the feasibility and benefit of intrapulmonary percussive ventilation (ipv) to improve deposition of inhaled radiolabelled aerosols in fibrotic lung regions of patients with idiopathic pulmonary fibrosis (ipf). phase 1 of the protocol aims to identify the highest ipv pressure that is tolerated by individual patients. secondary endpoints explore safety of ipv in ipf patients. phase 2 of the protocol is a crossover randomized trial where patients will inhale 99mtc-labelled diethylenetriamine pentaacetate (dtpa) aerosols with or without ipv. aerosol deposition in hrct-defined fibrotic regions of interest (roi) is described by single photon emission computed tomography (spect).


Eligibility criteria:
inclusion criteria: * diagnosis of ipf according to 2018 ats/ers/jrs/alat guidelines * affiliation to health insurance * signed informed consent exclusion criteria: * other chronic lung disease * airflow obstruction (fev1/fvc\<0.7) * history of congestive heart failure * history of ipf exacerbation * history of lung cancer * chronic cough precluding aerosol delivery and radioprotection * claustrophobia * 24h/24 oxygen therapy * any acute lung disease * any potentially transmissible lung infection * current or possible pregnancy and breastfeeding * contra-indications to ipv : emphysema, recent barotrauma, pneumothorax, pneumomediastinum * history of pneumothorax or pneumomediastinum * patient unable to hold a mouthpiece tightly * patient under legal protection (guardianship, curatorship) * contraindication to the administration of technescan dtpa

Keywords: aerosol deposition intrapulmonary percussive ventilation
evaluation of type 2 diabetes treatment

Conditions: Type2 Diabetes

Summary: the aim of this study is to analyze the efficacy of diabeton 60 mr as intensive sugar-lowering therapy into routine clinical practice, in patients for whom the treating physician has already decided to prescribe this medication. this concerns untreated newly diagnosed patients uncontrolled by diet, and patients uncontrolled by metformin.


Eligibility criteria:
inclusion criteria: - type 2 diabetes patients: * males and females, aged over 35 * currently treated: with diet only, or with metformin therapy for at least 3 months prior to inclusion * who have not been able to achieve target level of glycaemia, with glycated hemoglobin (hba1c) level exceeding 7%. exclusion criteria: patients with at least one of the following criteria are not included in the study: * type 1 diabetes * severe liver (alt and ast levels 2.5 times as high as upper level of normal range) or renal insufficiency (creatinin plasma level above 140 µmole/l) * patients who are on insulin therapy, or at risk to receive an insulin treatment in the next 4 months, according to physician judgment. * intolerance to gliclazide if such prescription was done in the past * pregnancy and breast-feeding * night workers or patients able to skip meals * presence of any contraindication listed in the smpc.
predicting the risk of non-culprit coronary artery disease after a heart attack

Conditions: Coronary Artery Disease; ST Elevation Myocardial Infarction; Ischemic Heart Disease

Summary: heart attacks caused by the complete blockage of a heart artery are treated by opening it with a stent. however, most people will also have 'non-culprit' narrowings found in their other arteries at this time. although in general people do better if these non-culprit narrowings are also treated with stents if they look severe, this process has problems. this is because narrowings that look severe may be stable and not cause any trouble. for these people a stent is a wasted procedure and unnecessary risk. on the other hand, narrowings that are currently left alone because they appear mild, may progress and cause a heart attack. participants who have had a heart attack will have a scan from inside the heart arteries during an angiogram (optical coherence tomography, oct) and a magnetic resonance angiogram (mra). if the investigators can show that it is possible to accurately predict which non-culprit narrowings are going to progress and which are going to stabilise, medical professionals may be able to better target their treatments after a heart attack.


Eligibility criteria:
inclusion criteria: * successful primary percutaneous coronary intervention (pci) within the previous week with no major complications at the index procedure * bystander disease in a non-culprit vessel planned for clinically indicated staged angiography +/- pci * able to provide written informed consent. exclusion criteria: * cardiogenic shock requiring intubation, inotropes or a mechanical support device * creatinine clearance \<30ml/min * prior coronary artery bypass grafting * life expectancy less than 3 years * pregnancy. * target lesion in the left main coronary artery * severe calcification or tortuosity that would threaten safe placement of a pressure wire or oct catheter * chronic total occlusion of a major epicardial vessel.

Keywords: optical coherence tomography non-culprit magnetic resonance imaging cardiac magnetic resonance stemi magnetic resonance angiography oct
intracanalicular dexamethasone insert for the treatment of inflammation and discomfort in dry eye disease (decided)

Conditions: Dry Eye

Summary: this prospective, single-center, randomized, double-masked, parallel comparison, sponsored study seeks to investigate the efficacy of intracanalicular dexamethasone insert (idi) on ameliorating the signs and symptoms of dry eye disease.


Eligibility criteria:
inclusion criteria: * diagnosis of dry eye disease * objective signs (schirmer's ii test \ =4 in at least 1 eye) * ocular inflammation presence confirmed by in-vivo confocal microscopy exclusion criteria: * history of diabetes * history of ocular surgery, corneal infection, or corneal injury within the last 3 months * active ocular allergies * active ocular infection * allergic to benzalkonium chloride
a study for treatment of paroxysmal atrial fibrillation (paf) with the thermocool smarttouch sf catheter and trupulse generator

Conditions: Atrial Fibrillation

Summary: the purpose of this study is to demonstrate safety and effectiveness of the ablation system (thermocool smarttouch sf \[stsf\] catheter and trupulse generator) when used for isolation of the atrial pulmonary veins (pvs) in treatment of participants with paroxysmal atrial fibrillation (paf).


Eligibility criteria:
inclusion criteria: * diagnosed with symptomatic paroxysmal atrial fibrillation (paf) defined as atrial fibrillation (af) that terminates spontaneously or with intervention within 7 days of onset. this paf is considered to be symptomatic if symptoms related to af are experienced by the participant * selected for af ablation procedure by pulmonary vein isolation (pvi) * failed at least one antiarrhythmic drug (aad) (class i to iv) as evidenced by recurrent symptomatic af, or intolerable or contraindicated to the aad * willing and capable of providing consent * able and willing to comply with all pre-, post- and follow-up testing and requirements. exclusion criteria: * previously known af secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause (example, documented obstructive sleep apnea, acute alcohol toxicity, morbid obesity {body mass index greater than \[\>\] 40 kilograms per meter square \[kg/m²\]}, renal insufficiency (with an estimated creatinine clearance less than \[\<\] 30 milliliters \[ml\]/ minute \[min\]/1.73 meter square \[m2\] ) * previous left atrium (la) ablation or surgery * patients known to require ablation outside the pulmonary vein (pv) region (example, atrioventricular reentrant tachycardia, atrioventricular nodal reentry tachycardia, atrial tachycardia, ventricular tachycardia and wolff-parkinson-white) * previously diagnosed with persistent af \[greater than (\>) 7 days in duration\] * severe dilatation of the left atrium (la) (left anterior descending artery \[lad\] \>50mm antero-posterior diameter in case of transthoracic echocardiography \[tte\])
wearable devices for patient monitoring in long qt syndrome

Conditions: Long QT Syndrome

Summary: the main research question of this study is whether wearable devices have utility in monitoring patients with long qt syndrome.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of long qt syndrome * aged 18 years or over * phone with ios version 15 or android os 9.0 or higher * able and willing to provide informed consent exclusion criteria: * unwilling or unable to give consent * ventricular pacing at recruitment * bundle branch block or pre-excitation at baseline
concerta lab school study

Conditions: Attention Deficit Hyperactivity Disorder

Summary: the purpose of this trial is to determine if the study medication, concerta (methylphenidate hcl), is safe and effective in improving academic performance and behavior in children with attention deficit hyperactivity disorder (adhd) when compared to placebo.

the hypothesis is that concerta (methylphenidate hcl) is safe and effective in improving academic performance and behavior in children with adhd when compared to placebo as demonstrated using specified study measures. this is a double-blind (neither participant nor investigator knows the name of the assigned study drug), randomized (study drug assigned by chance), placebo-controlled, crossover study evaluating the academic, behavioral and cognitive effects of concerta (methylphenidate hcl) on older children with adhd this means that all eligible children will receive treatment with methylphenidate hcl throughout the study (the titration and assessment periods) and inactive pill (placebo) on 1 of the 2 laboratory classroom days. on the other laboratory classroom day they will receive their regular dose of concerta (methylphenidate hcl). the primary efficacy variable in this study is the permanent product math test (permp) attempted score. secondary measures include: skamp (swanson, kotkin, agler, m-flynn, and pelham), tests of inattention, reading fluency and comprehension, and memory. assessments will be completed during each of the laboratory assessment days (12.5 hours). participants will be assessed for adverse events throughout the study. patients will initiate treatment with oral concerta (methylphenidate hcl) 18 mg at baseline and continue morning dosing with increases every 3 to 7 days until an optimal dose is achieved, up to the maximum of 54 mg/day. eligible patients will remain in the study for a maximum of 8 weeks.

Eligibility criteria:
inclusion criteria: * adhd diagnosis of all subtypes (except not otherwise specified) * patients with total or subscale attention deficit hyperactivity disorder rating scale (adhd rs-iv) scores \> =90th percentile relative to the general population of children by age and gender * patients currently receiving adhd medication must be inadequately managed on their current stimulant dose and meet this criteria at the screening visit * ability to read and understand english * ability to attend school regularly exclusion criteria: * estimated full scale iq score of 80 or below, severe learning disability * history of or current, primary diagnosis of: severe anxiety disorder, conduct disorder, psychotic disorders, pervasive developmental disorder, eating disorder, obsessive-compulsive disorder, sleep disorder, major depressive disorder, bipolar disorder, substance use disorder, chronic tic disorder, personal or family history of tourette's syndrome * weight \< 3rd percentile for age * history of hospitalization for treatment of a mood, anxiety, or psychotic disorder * history of failed response to methylphenidate

Keywords: adhd attention deficit hyperactivity disorder
immediate and delayed implant placement using socket shield technique and autogenous dentin graft

Conditions: Dental Implant; Tooth Loss; Socket Shield

Summary: one of the techniques that have been proposed to reduce the amount of bone resorption in anterior maxilla is the "socket shield (ss) ". this technique includes preservation of the facial segment of a root to be extracted and immediate implant placement. a technique of socket shield with delayed implantation using autogenous dentin graft for socket preservation, as an alternative to autogenous bone grafts, has shown predictable clinical and histological outcomes.


Eligibility criteria:
inclusion criteria: * patients with badly destructed or non-restorable maxillary anterior teeth when the labial cortical plate is still intact, and the thickness was found to be \<2mm in cbct. * patients with health status according to american society of anesthesiology (asa) i and ii. * patients who agree to participate in the study. exclusion criteria: * patients presenting with any systemic pathology or health condition that would inhibit the osseointegration process of the implants. * perforated labial cortical plate seen in cbct. * patients undergoing radiation therapy or history of radiation within the last two years. * drug or alcohol abuse
electronic health record strategies to promote diverse participation in research aim 2

Conditions: Patient Participation

Summary: based on the outcomes of the initial study (nct05348603), this optimization study will employ the most effective interventions (letters and messages) and distribute these communications to underrepresented minorities to further promote interest in research. optimized language will be distributed in english, spanish, portuguese, chinese, arabic, or haitian creole, based on preferred language identified in the patient profile in an electronic medical records system.

the primary objective of the optimization study is to examine the effectiveness on increasing interest in research of an optimized letter versus a generic letter; an optimized message versus a generic message; and an optimized letter and an optimized message versus a generic letter and a generic message. the secondary objective of the optimization study is to examine the effectiveness on increasing participation in research of an optimized letter versus a generic letter, an optimized message versus a generic message, an optimized letter and an optimized message versus a generic letter and a generic message.

Eligibility criteria:
inclusion criteria: * has an account with the online patient portal * has logged into the online patient portal at least once in the past year * has not set up a research profile exclusion criteria: * currently enrolled in a clinical trial * opted out of research * on active cancer treatment * active member of the study team

Keywords: online patient portal
rapid dose escalation of quetiapine versus conventional escalation in acute schizophrenic patients

Conditions: Schizophrenia

Summary: the purpose of the study is to compare the safety and tolerability of ir (immediate-release) quetiapine in a rapid escalation scheme with to the current approved label titration.


Eligibility criteria:
inclusion criteria: * men and women age ≥18 to ≤65 years with acute schizophrenia * provision of written informed consent prior to enrolment exclusion criteria: * meeting the criteria for any other (than schizophrenia) psychotic disorder not in full remission, concomitant organic mental disorder or mental retardation * patients with substance dependence * female patients who are pregnant, lactating or at risk of pregnancy

Keywords: schizophrenia
analysis of influencing factors of preoperative frailty in elderly patients with gastric cancer based on the health ecology theory

Conditions: Gastric Cancer; Frailty

Summary: frailty is common in patients with gastric cancer undergoing surgical treatment. preoperative frailty can lead to many adverse outcomes in patients after surgery. this study aims to comprehensively and systematically analyze the influencing factors of preoperative frailty in patients with gastric cancer based on the health ecology theory , to change some critical variable factors in the future, improving the overall prognosis of patients.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of gastric cancer * age over 60 years old * with clear surgical indication exclusion criteria: * malignant tumors in other parts of the body * severe cardiopulmonary complications * receive palliative surgery * have received preoperative radiotherapy and chemotherapy
virtual reality water friendly wound care

Conditions: Pain

Summary: using virtual reality as a form of distraction during a painful burn wound care procedure in addition to pain medication.

using virtual reality as a form of distraction during a painful burn wound care procedure in addition to pain medication.the aim of this study is to conduct a randomized controlled trial of virtual reality as a means to reduce pain during wound care in patients hospitalized for their burn injuries at harborview medical center burn center, and shriners hospitals for children in galveston, texas.

Eligibility criteria:
inclusion criteria: * age greater than or equal to 8 years * compliant and able to complete questionnaires * no history of psychiatric disorder * not demonstrating delirium, psychosis or any form of organic brain disorder * able to communicate verbally * english-speaking exclusion criteria: * age less than 8 years * not capable of indicating pain intensity * not capable of filling out study measures * evidence of traumatic brain injury * history of psychiatric disorder * demonstrating delirium, psychosis or any form of organic brain disorder and associated memory problems * unable to communicate orally * receiving prophylaxis for alcohol or drug withdrawal * developmental disability * any face/head/neck injuries that interfere with the use of virtual reality equipment * non-english speaking * extreme susceptibility to motion sickness * seizure history
randomised controlled trial of electroconvulsive therapy (ect) in relapse prevention of depression

Conditions: Depressive Disorder, Major

Summary: the purpose of the study is to determine if continuation electroconvulsive therapy (ect) is safe and effective in relapse prevention of depression.

randomized multicenter clinical trial with two parallel groups. patients with major depression (unipolar or bipolar), who have remitted with electroconvulsive therapy (ect) are eligible. all patients receive pharmacotherapy (venlafaxine target dose 300mg/day, and lithium target dose 0,5-0,8 mmol/l). the intervention is continuation unilateral ect weekly for the first 6 weeks thereafter every 2 weeks for one year. depressive relapse is the primary outcome measure.

Eligibility criteria:
inclusion criteria: 1. mini-plus verified major depressive episode (unipolar or bipolar). 2. ect within the last 3 weeks. 3. either remission defined as madrs \< 10 or 4. response defined as madrs \< 15 combined with patient assessed cgi-i of at least much improved exclusion criteria: 1. schizophrenia or schizoaffective disorder 2. addiction or dependence 3. kidney disease that contraindicates lithium treatment 4. vascular or heart disease that contraindicates venlafaxine treatment 5. uncontrolled epilepsia 6. age less that 18 7. pregnancy or lactation

Keywords: depressive disorder, major electroconvulsive therapy lithium carbonate venlafaxine
x-chromosome inactivation status and premature ovarian failure

Conditions: Premature Ovarian Failure

Summary: women who are affected with premature ovarian failure will exhibit skewed x-chromosome inactivation patterns compared to women with normal menstrual function (as defined by being pregnant), indicating a possible x-chromosome defect.

premature ovarian failure (pof) affects approximately 1% of women. for most women a cause is not found, but structural abnormalities of the x-chromosome commonly lead to pof, suggesting genes on the x-chromosome are necessary for normal ovarian function. it is known that certain gene mutations on the x-chromosome can lead to changes in the normal random pattern of x-chromosome inactivation in females. we propose to study x-inactivation patterns in a cohort of women with idiopathic pof, and compare their pattern to a mean age-matched cohort of women with normal menstrual function. we hypothesize that some women with pof will show skewed x-inactivation, suggesting a mutation on the x-chromosome as the etiology of their pof.

Eligibility criteria:
inclusion criteria: * women diagnosed with pof. * a chromosomal analysis must have been performed to evaluate x-chromosomal abnormalities, and the results are known to be normal. exclusion criteria: * patients who have a known etiology for their pof and/or an inability to obtain karyotype results for these patients or unknown x-chromosome abnormalities.

Keywords: premature ovarian failure x-chromosome inactivation